Iratumumab
Appearance
This article needs additional citations for verification. (August 2012) |
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | CD30 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6358H9830N1682O1992S38 |
Molar mass | 142922.64 g·mol−1 |
![]() ![]() |
Iratumumab is a human monoclonal antibody used in the treatment of oncological diseases such as relapsed refractory CD30-positive lymphoma including Hodgkin's disease.[1]
This drug was developed by Medarex, which was later acquired by Bristol-Myers Squibb.
The FDA granted orphan drug designation for Hodgkin's lymphoma in 2004. In 2009, development was suspended with no explanation given.[2]
References
[edit]- ^ Statement On A Nonproprietary Name Adopted By The USAN Council – Iratumumab, American Medical Association.
- ^ "Iratumumab". AdisInsight. Retrieved 30 January 2017.